NCT00203125View on ClinicalTrials.gov

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions
Parkinson's Disease
Interventions
DRUG

rasagiline mesylate

0.5 or 1 mg oral, once-daily

OTHER

tyramine

50 mg once daily

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00203125 - A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study. | Biotech Hunter | Biotech Hunter